Rxivist logo

Clinical observations of low molecular weight heparin in relieving inflammation in COVID-19 patients: A retrospective cohort study

By Chen Shi, Cong Wang, Hanxiang Wang, Chao Yang, Fei Cai, Fang Zeng, Fang Cheng, Yihui Liu, Taotao Zhou, Bin Deng, Israel Vlodavsky, Jin-Ping Li, Yu Zhang

Posted 01 Apr 2020
medRxiv DOI: 10.1101/2020.03.28.20046144

BackgroundOn March 11, 2020, the World Health Organization declared its assessment of COVID-19 as a global pandemic. Effective therapeutic drugs are urgently needed to improve the overall prognosis of patients, but currently no such drugs are available. MethodsPatients in the study were divided into a heparin and a control group based on whether low molecular weight heparin (LMWH) was used. D-dimer, C-reactive protein (CRP), peripheral blood lymphocyte percentage, interleukin-6, and other indices in 42 patients with novel coronavirus pneumonia were retrospectively analyzed to compare and evaluate the progress of patients before and after LMWH treatment. ResultsCompared to the control group, D-dimer levels in the heparin group significantly increased before treatment, and there was no significant difference after treatment. There was no significant difference in the change of CRP levels between the two groups of patients before and after LMWH treatment, and levels for both groups were significantly lower after, compared to before, treatment. Compared to the control group, patients in the heparin group had a higher percentage of lymphocytes after treatment and lower levels of interleukin-6; these differences were statistically significant. ConclusionsUnder conventional antiviral treatment regimens, LMWH can improve hypercoagulability, inhibit IL-6 release, and counteract IL-6 biological activity in patients. LMWH has potential antiviral effects and can help delay or block inflammatory cytokine storms. It can also increase the lymphocytes (LYM%)of patients and has the potential for treatment of COVID-19.

Download data

  • Downloaded 10,576 times
  • Download rankings, all-time:
    • Site-wide: 967
    • In pharmacology and therapeutics: 3
  • Year to date:
    • Site-wide: 6,250
  • Since beginning of last month:
    • Site-wide: 14,856

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide